HPV-tested de-escalated radiation for HPV-related throat cancer
Part of Cancer clinical trials.
This Phase 2 study uses HPV test results from your tumor to safely lower (de-intensify) the strength of radiation for some HPV-positive oropharyngeal throat cancers. It aims to reduce side effects while keeping cancer control effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and can sign consent and follow all study steps for the full study period
- Your throat cancer is squamous cell carcinoma in the oropharynx (back of the throat)
- Your cancer is HPV-related and “p16 positive,” confirmed by NavDx and a tumor staining test
- Your cancer can be treated with definitive or added-on (adjuvant) radiation as part of standard care
- If your cancer is T3–T4 and/or has lymph node spread (N+), you must plan to receive chemotherapy at the same time as radiation
- You can’t have cancer spread to distant organs, and you haven’t had radiation to the head/neck before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether giving a less intense (de-escalated) radiation plan can work for certain people with HPV-related oropharyngeal throat cancer. It uses HPV blood testing and scans to help guide treatment, aiming to keep cancer control while reducing treatment side effects.
This Phase 2 trial tests whether people with HPV-positive oropharyngeal (throat) cancer who look “lower risk” can safely receive less intensive treatment. It uses HPV blood test results and cancer staging scans to guide whether treatment can be de-escalated.
This trial tests whether giving less radiation after surgery is safe and effective for people with early-stage HPV-related throat cancer. It aims to reduce side effects while still controlling the cancer.
This trial tests whether a lower dose of radiation to the neck is safe and effective for people with HPV-related oropharyngeal cancer. It may reduce side effects while still treating the cancer.
This trial tests whether using a de-escalated (lower/intensity-reduced) radiation approach can treat HPV-positive oropharyngeal squamous cell carcinoma. It may help reduce side effects while still keeping the cancer under control.
This trial tests whether we can safely use lower doses of radiation for people with HPV-related throat cancer, while still targeting the areas that need it. The goal is to reduce side effects without lowering the chance of a cure.
Hear when a new Squamous Cell Carcinoma of the Oropharynx trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.